Medscape is available in 5 Language Editions – Choose your Edition here.


Sphingomyelinase Deficiency

  • Author: Lynne Ierardi-Curto, MD, PhD; Chief Editor: Luis O Rohena, MD  more...
Updated: Aug 18, 2016


Niemann-Pick disease (NPD) is a lipid storage disorder that results from the deficiency of a lysosomal enzyme, acid sphingomyelinase. The original description of NPD referred to what is currently termed NPD type A, which is a fatal disorder of early childhood characterized by failure to thrive, hepatosplenomegaly, and a rapidly progressive neurodegenerative course that leads to death by age 2-3 years.

Since this original description, other forms of NPD have been described. NPD type B is a milder, nonneuronopathic form with later onset and longer survival, sometimes into adulthood. NPD type C, a rarer form, results from defects in cholesterol metabolism. Both NPD types A and B are inherited as autosomal recessive traits.



Niemann-Pick disease (NPD) types A and B result from the deficient activity of sphingomyelinase, a lysosomal enzyme encoded by the SMPD1 gene located on bands 11p15.1-p15.4.[1, 2] The enzymatic defect results in pathologic accumulation of sphingomyelin (which is a ceramide phospholipid) and other lipids in the monocyte-macrophage system, the primary site of pathology in patients with NPD. Additional progressive deposition of sphingomyelin in the CNS results in the neurodegenerative course observed in NPD type A, which shares systemic disease manifestations with NPD type B. The severity of systemic involvement varies in affected individuals. Systemic involvement includes progressive lung disease, hepatosplenomegaly, short stature, and pancytopenia.[3]

Individuals with NPD types A and B typically have less than 10% residual acid sphingomyelinase enzyme activity. The complete sphingomyelinase genomic region has been isolated and sequenced. Three common mutations (L302P, 1bp del fsP330, R496L) account for approximately 90% of NPD type A alleles in the Ashkenazi Jewish population. The deltaR608 mutation is a common mutation that causes NPD type B.



Niemann-Pick disease (NPD) types A and B result from a deficiency of acid sphingomyelinase and lysosomal accumulation of sphingomyelin.

NPD types A and B

These disorders result from deficient activity of sphingomyelinase, a lysosomal enzyme encoded by a gene located on chromosome 11 (11p15.1 to p15.4). Enzymatic defects result in pathologic accumulation of sphingomyelin, a ceramide phospholipid, and other lipids in monocyte-macrophage systems, the primary site of pathology.

NPD type A is characterized by early-onset, progressive neurodegenerative course; systemic disease manifestations, including massive hepatosplenomegaly, interstitial lung disease, and cherry-red macula; and death in early childhood. Traditionally, NPD type B was considered a milder, later-onset form of the disorder that was non-neuronopathic. However, some overlap exists between these 2 forms of NPD, with a broad range and severity of somatic and neurologic features noted in patients classified as NPD type B. Complete sphingomyelinase genomic regions have been isolated and sequenced, and a number of mutations that cause NPD types A and B are identified, including single base substitutions and small deletions.



Racial differences in incidence

Niemann-Pick disease (NPD) is a rare disorder that occurs in persons of all races,[4, 5] although NPD type A is more common in persons of Ashkenazi Jewish descent. Guidelines for carrier screening for genetic disorders in individuals of Ashkenazi Jewish descent have been established.[6] NPD type B occurs worldwide but has a higher frequency in the Maghreb region of North Africa and Saudi Arabia and in individuals of Turkish descent.[7]

Sexual differences in incidence

NPD types A and B are autosomal recessive disorders (see image below), equally affecting males and females.

Autosomal recessive inheritance pattern. Autosomal recessive inheritance pattern.

Age-related differences in incidence

Patients with NPD type A disease develop symptoms as early as age 3 months and die by age 3 years. In contrast, patients with type B disease may survive to adulthood, although most present in childhood with hepatosplenomegaly.

NPD type A is a fatal disorder of infancy. Hepatosplenomegaly develops by age 6 months and development does not progress beyond age 12 months. A relentless neurodegenerative course then follows, with death by age 21 months.

NPD type B has a variable age of presentation but frequently appears early in childhood when hepatosplenomegaly is detected and symptoms of lung involvement may occur. Patients with NPD type B primarily have visceral involvement, sometimes massive, and often survive into adulthood.



Niemann-Pick disease (NPD) type A disease is fatal in early childhood. The clinical presentation and course of NPD type A is relatively uniform and characterized by normal appearance at birth, followed by progressive hepatosplenomegaly from age 3 months and severe, neurodegenerative course leading to death by age 3 years.

In contrast to the stereotyped type A phenotype, the clinical presentation and the course of patients with NPD type B disease are more variable with respect to clinical findings, age of onset, and severity of symptoms. Most patients are diagnosed in infancy or childhood, when enlargement of the liver and the spleen are detected during routine physical examination. Survival to adulthood is typical.



Patients with NPD type B are at risk for splenic rupture and should avoid contact sports.

A small number of patients with NPD type B develop liver failure and may be candidates for liver transplantation.

Pulmonary disease is progressive in patients with NPD type B disease and may result in oxygen dependence.


Patients with NPD type A develop progressive failure to thrive, sphingomyelin accumulation, liver dysfunction, and neurodegeration beginning at age 3 months and ending with death by age 3 years. Patients with NPD type B may develop extensive involvement of the spleen, liver, and lungs; these patients often survive into adulthood. Mild and progressive neurologic findings may occur in NPD type B; however, progressive neurodegeneration is limited to NPD type A.

A study by Cassiman et al found that in patients with chronic neurovisceral acid sphingomyelinase deficiency (intermediate NPD A/B; NPD B variant), the most frequent causes of death were neurodegenerative disease (23.1%), respiratory disease (23.1%), and liver disease (19.2%).[8]


Patient Education

Counsel families regarding genetic risk and the availability of prenatal testing.

For patient education resources, see the Cholesterol Center, as well as High Cholesterol, Cholesterol FAQs, and Cholesterol Drugs

Contributor Information and Disclosures

Lynne Ierardi-Curto, MD, PhD Attending Physician, Division of Metabolism, Children's Hospital of Philadelphia

Disclosure: Nothing to disclose.

Chief Editor

Luis O Rohena, MD Chief, Medical Genetics, San Antonio Military Medical Center; Assistant Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Assistant Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Luis O Rohena, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American College of Medical Genetics and Genomics, American Society of Human Genetics

Disclosure: Nothing to disclose.


James Bowman, MD Senior Scholar of Maclean Center for Clinical Medical Ethics, Professor Emeritus, Department of Pathology, University of Chicago

James Bowman, MD is a member of the following medical societies: Alpha Omega Alpha, American Society for Clinical Pathology, American Society of Human Genetics, Central Society for Clinical Research, and College of American Pathologists

Disclosure: Nothing to disclose.

David Flannery, MD, FAAP, FACMG Vice Chair of Education, Chief, Section of Medical Genetics, Professor, Department of Pediatrics, Medical College of Georgia

David Flannery, MD, FAAP, FACMG is a member of the following medical societies: American Academy of Pediatrics and American College of Medical Genetics

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

  1. Camoletto PG, Vara H, Morando L, et al. Synaptic vesicle docking: sphingosine regulates syntaxin1 interaction with Munc18. PLoS ONE. 2009. 4(4):e5310. [Medline].

  2. Jenkins RW, Canals D, Hannun YA. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal. 2009 Jun. 21(6):836-46. [Medline].

  3. Ambrosio C, Serra S, Alexandre M, Malcata A. [Arthralgia, bone pain, positive antinuclear antibodies and thrombocytopenia...diagnosis: Niemann-Pick disease]. Acta Reumatol Port. 2009 Jan-Mar. 34(1):102-5. [Medline].

  4. Cho YU, Chae JD, Lee WM, et al. [A Case of a Korean Adult Affected by Type B Niemann-Pick Disease: Secondary Sea-blue Histiocytosis and Molecular Characterization.]. Korean J Lab Med. 2009 Apr. 29(2):97-103. [Medline].

  5. Rodriguez-Pascau L, Gort L, Schuchman EH, Vilageliu L, Grinberg D, Chabas A. Identification and characterization of SMPD1 mutations causing Niemann-Pick types A and B in Spanish patients. Hum Mutat. 2009 Mar 18. [Medline].

  6. [Guideline] Langlois S, Wilson RD. Carrier screening for genetic disorders in individuals of Ashkenazi Jewish descent. J Obstet Gynaecol Can. 2006 Apr. 28(4):324-43. [Medline]. [Full Text].

  7. Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet. 2002 Dec. 71(6):1413-9. [Medline]. [Full Text].

  8. Cassiman D, Packman S, Bembi B, et al. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann-Pick disease type B and B variant): Literature review and report of new cases. Mol Genet Metab. 2016 Jul. 118 (3):206-13. [Medline].

  9. Vykuntaraju KN, Lokanatha H, Shivananda. Niemann-Pick disease type A presenting as unilateral tremors. Indian Pediatr. 2012 Nov. 49(11):919-20. [Medline].

  10. Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr. 2006 Oct. 149(4):554-9. [Medline].

  11. Shah AJ, Kapoor N, Crooks GM, Parkman R, Weinberg KI, Wilson K, et al. Successful hematopoietic stem cell transplantation for Niemann-Pick disease type B. Pediatrics. 2005 Oct. 116(4):1022-5. [Medline].

  12. McGovern MM, Lippa N, Bagiella E, Schuchman EH, Desnick RJ, Wasserstein MP. Morbidity and mortality in type B Niemann-Pick disease. Genet Med. 2013 Aug. 15(8):618-23. [Medline].

Autosomal recessive inheritance pattern.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.